Identification

Name
Chlorothiazide
Accession Number
DB00880  (APRD00721)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)

Structure
Thumb
Synonyms
  • 6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
  • 6-chloro-7-Sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
  • Chlorothiazid
  • Chlorothiazide
  • Chlorothiazidum
  • Chlorthiazide
  • Clorotiazida
  • Mechlozid
  • Uroflux
Product Ingredients
IngredientUNIICASInChI Key
Chlorothiazide SodiumSN86FG7N2K7085-44-1CPIWHAFLBZQYLQ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorothiazide SodiumInjection500 mg/1IntravenousAkorn2012-08-13Not applicableUs
DiurilSuspension250 mg/5mLOralSalix Pharmaceuticals1962-02-15Not applicableUs
Sodium DiurilInjection.5 mg/18mLIntravenousOak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)1958-10-03Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ChlorothiazideTablet500 mg/1OralWest Ward Pharmaceutical2005-08-30Not applicableUs
ChlorothiazideTablet500 mg/1OralGolden State Medical Supply2005-08-302017-10-26Us00143 1210 01 nlmimage10 b304d9c6
ChlorothiazideTablet250 mg/1OralMylan Pharmaceuticals1975-06-26Not applicableUs
ChlorothiazideTablet250 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
ChlorothiazideTablet250 mg/1OralWest Ward Pharmaceutical2005-08-30Not applicableUs
ChlorothiazideTablet250 mg/1OralGolden State Medical Supply2005-08-302017-10-26Us
ChlorothiazideTablet500 mg/1OralMylan Pharmaceuticals1975-07-17Not applicableUs00378 0162 01 nlmimage10 b83ddc0e
ChlorothiazideInjection, powder, lyophilized, for solution500 mg/18mLIntravenousFresenius Kabi2009-10-21Not applicableUs
Chlorothiazide SodiumInjection, powder, lyophilized, for solution500 mg/18mLIntravenousSagent Pharmaceuticals2015-10-12Not applicableUs
Chlorothiazide SodiumInjection, powder, lyophilized, for solution500 mg/18mLIntravenousAmerican Regent2015-04-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Supres 150 TabChlorothiazide (150 mg) + Methyldopa (250 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1972-12-312000-06-14Canada
Supres 250 TabChlorothiazide (250 mg) + Methyldopa (250 mg)TabletOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1972-12-312000-06-14Canada
Categories
UNII
77W477J15H
CAS number
58-94-6
Weight
Average: 295.723
Monoisotopic: 294.948824782
Chemical Formula
C7H6ClN3O4S2
InChI Key
JBMKAUGHUNFTOL-UHFFFAOYSA-N
InChI
InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)
IUPAC Name
6-chloro-1,1-dioxo-4H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1

Pharmacology

Indication

Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Structured Indications
Pharmacodynamics

Like other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Mechanism of action

As a diuretic, chlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like chlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of chlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

TargetActionsOrganism
ASolute carrier family 12 member 3
inhibitor
Human
ACarbonic anhydrase 1
inhibitor
Human
ACarbonic anhydrase 2
inhibitor
Human
ACarbonic anhydrase 4
inhibitor
Human
Absorption

Rapidly absorbed following oral administration.

Volume of distribution
Not Available
Protein binding

Approximately 40% bound to plasma proteins.

Metabolism

Chlorothiazide is not metabolized but is eliminated rapidly by the kidney.

Route of elimination

Chlorothiazide is not metabolized but is eliminated rapidly by the kidney. After oral doses, 10 to 15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Half life

45-120 minutes

Clearance
Not Available
Toxicity

Oral, rat LD50: > 10 g/kg. Signs of overdose include those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered hypokalemia may accentuate cardiac arrhythmias.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Chlorothiazide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Chlorothiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Chlorothiazide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Chlorothiazide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Chlorothiazide.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Chlorothiazide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Chlorothiazide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acemetacin.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Chlorothiazide.Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Chlorothiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Chlorothiazide.Experimental, Investigational
AlaproclateAlaproclate may increase the hyponatremic activities of Chlorothiazide.Experimental
AlclofenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Chlorothiazide.Approved
AlcuroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Chlorothiazide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorothiazide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Chlorothiazide.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Chlorothiazide.Approved
AlminoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorothiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorothiazide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Chlorothiazide.Illicit
AlprenololAlprenolol may increase the hypotensive activities of Chlorothiazide.Approved, Withdrawn
AmbrisentanChlorothiazide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Chlorothiazide.Approved
AmifostineChlorothiazide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Chlorothiazide.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Chlorothiazide.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Chlorothiazide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Chlorothiazide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amyl Nitrite.Approved
AndrographolideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Chlorothiazide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Chlorothiazide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Chlorothiazide.Investigational
AnisodamineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Chlorothiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Chlorothiazide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Chlorothiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Chlorothiazide.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Chlorothiazide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Chlorothiazide.Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Chlorothiazide.Approved
AtracuriumThe serum concentration of Chlorothiazide can be increased when it is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe serum concentration of Chlorothiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Chlorothiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Chlorothiazide.Investigational
BalsalazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Chlorothiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Chlorothiazide.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Chlorothiazide.Investigational
BenactyzineThe serum concentration of Chlorothiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Chlorothiazide.Approved, Investigational
BendazacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Chlorothiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Chlorothiazide.Withdrawn
BenorilateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Chlorothiazide can be increased when it is combined with Benzatropine.Approved
BepridilChlorothiazide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Chlorothiazide.Approved
BethanidineBethanidine may increase the hypotensive activities of Chlorothiazide.Approved
BevoniumThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Chlorothiazide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Chlorothiazide.Experimental
BimatoprostChlorothiazide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Chlorothiazide can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Chlorothiazide.Approved
BornaprineThe serum concentration of Chlorothiazide can be increased when it is combined with Bornaprine.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Chlorothiazide.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
BQ-123Chlorothiazide may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Chlorothiazide.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Chlorothiazide.Experimental
BromfenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorothiazide.Approved, Investigational
BucillamineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Chlorothiazide.Approved
BufexamacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bufexamac.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Chlorothiazide.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorothiazide.Approved, Investigational
BupranololChlorothiazide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorothiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorothiazide.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Chlorothiazide.Experimental
CafedrineChlorothiazide may increase the hypotensive activities of Cafedrine.Investigational
CalcidiolChlorothiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolChlorothiazide may increase the hypercalcemic activities of Calcipotriol.Approved
CalciumChlorothiazide may decrease the excretion rate of Calcium which could result in a higher serum level.Approved, Nutraceutical
Calcium AcetateChlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium CarbonateChlorothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Calcium CitrateChlorothiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateChlorothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateChlorothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateChlorothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateChlorothiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateChlorothiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium laevulateChlorothiazide may decrease the excretion rate of Calcium laevulate which could result in a higher serum level.Experimental
Calcium pangamateChlorothiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateChlorothiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Chlorothiazide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Chlorothiazide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Chlorothiazide.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Chlorothiazide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorothiazide.Illicit, Investigational, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Chlorothiazide.Withdrawn
CarprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Chlorothiazide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carvedilol.Approved, Investigational
CaseinChlorothiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Chlorothiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chlorothiazide.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorothiazide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Chlorothiazide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
CicletanineChlorothiazide may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorothiazide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Chlorothiazide.Approved, Investigational
CitalopramCitalopram may increase the hyponatremic activities of Chlorothiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Chlorothiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Chlorothiazide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Chlorothiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Chlorothiazide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Chlorothiazide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Chlorothiazide.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorothiazide.Approved
ClonixinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Clonixin.Approved
CloranololChlorothiazide may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Chlorothiazide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorothiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Chlorothiazide.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Chlorothiazide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Chlorothiazide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Chlorothiazide.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Chlorothiazide.Approved
CurcuminThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Curcumin.Investigational
CyclopenthiazideChlorothiazide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopentolateThe serum concentration of Chlorothiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Chlorothiazide.Approved
CymarinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cymarin.Experimental
D-LimoneneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Chlorothiazide.Investigational
DarifenacinThe serum concentration of Chlorothiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
DelaprilChlorothiazide may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Chlorothiazide.Investigational
DeserpidineChlorothiazide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorothiazide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Chlorothiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Chlorothiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Chlorothiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Chlorothiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Chlorothiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Chlorothiazide.Vet Approved
DexetimideThe serum concentration of Chlorothiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Chlorothiazide.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorothiazide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorothiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorothiazide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorothiazide.Approved, Investigational
DiazoxideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Chlorothiazide can be increased when it is combined with Dicyclomine.Approved
diethylnorspermineChlorothiazide may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Chlorothiazide.Approved
DiflunisalThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
DifluprednateDifluprednate may increase the hypokalemic activities of Chlorothiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Chlorothiazide.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorothiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorothiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorothiazide.Experimental, Illicit
DihydrotachysterolChlorothiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Chlorothiazide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorothiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Chlorothiazide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Chlorothiazide.Approved
DofetilideChlorothiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Chlorothiazide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Chlorothiazide.Approved
DoxercalciferolChlorothiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorothiazide.Investigational
DroxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorothiazide.Approved
DuloxetineChlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with E-6201.Investigational
EfonidipineChlorothiazide may increase the hypotensive activities of Efonidipine.Approved
EmeproniumThe serum concentration of Chlorothiazide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Chlorothiazide.Approved, Vet Approved
EnalaprilatChlorothiazide may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Chlorothiazide.Experimental
EpanololChlorothiazide may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Chlorothiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Chlorothiazide.Approved
EpoprostenolChlorothiazide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chlorothiazide.Approved
EquileninEquilenin may increase the hypokalemic activities of Chlorothiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Chlorothiazide.Approved
ErgocalciferolChlorothiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Chlorothiazide.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Chlorothiazide.Approved
EstroneEstrone may increase the hypokalemic activities of Chlorothiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Chlorothiazide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Etacrynic acid.Approved
EtanautineThe serum concentration of Chlorothiazide can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Chlorothiazide.Approved
EthenzamideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Chlorothiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorothiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoperidoneEtoperidone may increase the hyponatremic activities of Chlorothiazide.Withdrawn
EtoricoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorothiazide.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Chlorothiazide can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Evening primrose oil.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Chlorothiazide.Approved
FenoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorothiazide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Chlorothiazide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Chlorothiazide.Approved, Investigational
FloctafenineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Chlorothiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Chlorothiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
FlunixinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Chlorothiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Chlorothiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Chlorothiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Chlorothiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Chlorothiazide.Approved
FlurbiprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluvoxamineFluvoxamine may increase the hyponatremic activities of Chlorothiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Chlorothiazide.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Chlorothiazide.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Chlorothiazide.Approved, Vet Approved
GallamineThe serum concentration of Chlorothiazide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Chlorothiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Chlorothiazide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Chlorothiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorothiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorothiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorothiazide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Chlorothiazide.Approved
GlycopyrroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Chlorothiazide.Approved
GuanazodineChlorothiazide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Chlorothiazide.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Guanfacine.Approved, Investigational
GuanoclorChlorothiazide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzChlorothiazide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanChlorothiazide may increase the hypotensive activities of Guanoxan.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Chlorothiazide.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorothiazide.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Chlorothiazide.Experimental
HE3286HE3286 may increase the hypokalemic activities of Chlorothiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Chlorothiazide.Approved, Illicit, Investigational
HexamethoniumThe serum concentration of Chlorothiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved
HigenamineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Chlorothiazide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Chlorothiazide.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorothiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorothiazide.Approved, Illicit
HyoscyamineThe serum concentration of Chlorothiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Chlorothiazide.Investigational
Imidazole salicylateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Chlorothiazide.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Chlorothiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Chlorothiazide.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Chlorothiazide.Approved
IndenololChlorothiazide may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Chlorothiazide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Chlorothiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Chlorothiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorothiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Chlorothiazide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Chlorothiazide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorothiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorothiazide.Approved
Ipratropium bromideThe serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Chlorothiazide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Chlorothiazide.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Chlorothiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Chlorothiazide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Chlorothiazide.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Chlorothiazide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Chlorothiazide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Chlorothiazide.Investigational
IvabradineChlorothiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Chlorothiazide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorothiazide.Approved, Investigational
KetoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Chlorothiazide.Approved
LacidipineChlorothiazide may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
LeflunomideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chlorothiazide.Approved, Investigational
LevodopaChlorothiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorothiazide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Chlorothiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorothiazide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Chlorothiazide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Chlorothiazide.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Chlorothiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorothiazide.Approved
LinsidomineChlorothiazide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Chlorothiazide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Chlorothiazide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumChlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorothiazide.Illicit
LofexidineChlorothiazide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Chlorothiazide.Approved
LoxoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanChlorothiazide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineChlorothiazide may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Chlorothiazide.Approved, Investigational
MasoprocolThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Masoprocol.Approved, Investigational
MazaticolThe serum concentration of Chlorothiazide can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Chlorothiazide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Chlorothiazide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Chlorothiazide.Approved
Mefenamic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Chlorothiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Chlorothiazide.Experimental
MesalazineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Metamizole.Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorothiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorothiazide.Approved, Illicit
MethanthelineThe serum concentration of Chlorothiazide can be increased when it is combined with Methantheline.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Chlorothiazide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved
MethoserpidineChlorothiazide may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Chlorothiazide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Metipranolol.Approved
MetixeneThe serum concentration of Chlorothiazide can be increased when it is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Chlorothiazide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Chlorothiazide.Approved, Investigational
MetyrosineChlorothiazide may increase the hypotensive activities of Metyrosine.Approved
MibefradilChlorothiazide may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Chlorothiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Chlorothiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Chlorothiazide.Approved
MinaprineMinaprine may increase the hypotensive activities of Chlorothiazide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Chlorothiazide.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Chlorothiazide.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Chlorothiazide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Chlorothiazide.Approved
MofebutazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorothiazide.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
MuzolimineChlorothiazide may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Chlorothiazide.Approved, Investigational
NabumetoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naftifine.Approved
NaftopidilChlorothiazide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorothiazide.Approved
NaproxenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Chlorothiazide.Investigational
NebivololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Chlorothiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Chlorothiazide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Chlorothiazide.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Chlorothiazide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineChlorothiazide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineChlorothiazide may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Chlorothiazide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Chlorothiazide.Approved
NitrendipineChlorothiazide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Chlorothiazide.Approved
NitroaspirinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Chlorothiazide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Chlorothiazide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Chlorothiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Chlorothiazide.Approved, Illicit
ObinutuzumabChlorothiazide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Chlorothiazide.Withdrawn
OleandrinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Chlorothiazide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chlorothiazide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Chlorothiazide.Approved
OlopatadineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatChlorothiazide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Chlorothiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Chlorothiazide.Approved
OrgoteinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Chlorothiazide can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Chlorothiazide can be increased when it is combined with Otilonium.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Chlorothiazide can be increased when it is combined with Oxitropium.Investigational
OxprenololChlorothiazide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Chlorothiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorothiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorothiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenoniumThe serum concentration of Chlorothiazide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorothiazide.Approved, Vet Approved
PancuroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Chlorothiazide.Approved
ParecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Chlorothiazide.Approved
ParicalcitolChlorothiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Chlorothiazide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorothiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Chlorothiazide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Chlorothiazide.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorothiazide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Chlorothiazide.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Chlorothiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Chlorothiazide.Approved, Investigational, Withdrawn
PhenglutarimideThe serum concentration of Chlorothiazide can be increased when it is combined with Phenglutarimide.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Chlorothiazide.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Chlorothiazide.Experimental
PhenoxybenzamineChlorothiazide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Chlorothiazide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Chlorothiazide.Approved
PhenylbutazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Chlorothiazide.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorothiazide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorothiazide.Approved, Investigational
PipecuroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Chlorothiazide.Approved
PirenzepineThe serum concentration of Chlorothiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Chlorothiazide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Chlorothiazide.Approved
PiroxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Chlorothiazide.Withdrawn
PolythiazideChlorothiazide may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Chlorothiazide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Chlorothiazide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Chlorothiazide.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Chlorothiazide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Chlorothiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Chlorothiazide.Experimental, Investigational
PrimidonePrimidone may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
ProcyclidineThe serum concentration of Chlorothiazide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropanthelineThe serum concentration of Chlorothiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Chlorothiazide can be increased when it is combined with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorothiazide.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Chlorothiazide.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Proscillaridin.Experimental
PTC299The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Chlorothiazide can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Chlorothiazide.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Chlorothiazide.Approved
RasagilineRasagiline may increase the hypotensive activities of Chlorothiazide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorothiazide.Approved
RemikirenRemikiren may increase the hypotensive activities of Chlorothiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
RescinnamineChlorothiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorothiazide.Approved, Investigational
ResveratrolThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Chlorothiazide.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Chlorothiazide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Riociguat.Approved
RisperidoneChlorothiazide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
RituximabChlorothiazide may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Chlorothiazide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorothiazide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Chlorothiazide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Chlorothiazide.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Chlorothiazide.Approved
SafrazineSafrazine may increase the hypotensive activities of Chlorothiazide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Chlorothiazide.Approved
SalsalateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salsalate.Approved
SaprisartanChlorothiazide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Chlorothiazide.Approved
ScopolamineThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Chlorothiazide.Approved, Investigational, Vet Approved
SelexipagChlorothiazide may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Chlorothiazide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorothiazide.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Chlorothiazide.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Chlorothiazide.Approved, Investigational
SitaxentanChlorothiazide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Chlorothiazide.Approved
Sodium phosphateChlorothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Chlorothiazide can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Chlorothiazide.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Chlorothiazide.Approved
SpiraprilChlorothiazide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Chlorothiazide.Approved
SRT501The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorothiazide.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Chlorothiazide.Approved, Investigational
TalinololChlorothiazide may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Chlorothiazide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorothiazide.Approved
TarenflurbilThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Telmisartan.Approved, Investigational
TemocaprilChlorothiazide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Chlorothiazide.Approved
TeriflunomideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinChlorothiazide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineChlorothiazide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Chlorothiazide.Approved, Investigational, Withdrawn
TheodrenalineChlorothiazide may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorothiazide.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneChlorothiazide may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenChlorothiazide may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Chlorothiazide.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Chlorothiazide.Approved
TinoridineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Chlorothiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Chlorothiazide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorothiazide.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorothiazide.Approved
TolazolineTolazoline may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorothiazide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorothiazide.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolmetin.Approved
TolonidineChlorothiazide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Chlorothiazide.Approved
TolterodineThe serum concentration of Chlorothiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateChlorothiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Chlorothiazide.Approved
ToremifeneChlorothiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorothiazide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Chlorothiazide.Approved
TranilastThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Chlorothiazide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Chlorothiazide.Approved
TravoprostTravoprost may increase the hypotensive activities of Chlorothiazide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Chlorothiazide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Chlorothiazide.Approved
TribenosideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideChlorothiazide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Chlorothiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Chlorothiazide.Experimental
TrimethaphanThe serum concentration of Chlorothiazide can be increased when it is combined with Trimethaphan.Approved, Investigational
TriptolideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Chlorothiazide.Investigational, Withdrawn
TropatepineThe serum concentration of Chlorothiazide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Chlorothiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Chlorothiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Chlorothiazide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Chlorothiazide.Approved, Investigational
UnoprostoneChlorothiazide may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Chlorothiazide.Investigational
ValdecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Chlorothiazide.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Chlorothiazide.Approved
VecuroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Chlorothiazide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Chlorothiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorothiazide.Approved, Investigational
VincamineChlorothiazide may increase the hypotensive activities of Vincamine.Experimental
VinpocetineChlorothiazide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Chlorothiazide.Approved, Investigational
XipamideChlorothiazide may increase the hypotensive activities of Xipamide.Experimental
XylometazolineChlorothiazide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Chlorothiazide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Chlorothiazide.Withdrawn
ZofenoprilChlorothiazide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Eugene S. Barabas, "Water soluble complex of a poly (vinyl lactam) and chlorothiazide and process for producing same." U.S. Patent US4713238, issued December, 1985.

US4713238
General References
Not Available
External Links
Human Metabolome Database
HMDB15018
KEGG Drug
D00519
KEGG Compound
C07461
PubChem Compound
2720
PubChem Substance
46507032
ChemSpider
2619
BindingDB
39351
ChEBI
3640
ChEMBL
CHEMBL842
Therapeutic Targets Database
DAP000605
PharmGKB
PA448953
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Chlorothiazide
ATC Codes
C03AA04 — ChlorothiazideC03AB04 — Chlorothiazide and potassiumC03AH01 — Chlorothiazide, combinationsG01AE10 — Combinations of sulfonamides
MSDS
Download (72.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionCardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases1
4Enrolling by InvitationTreatmentHeart Failure, Unspecified1
Not AvailableCompletedScreeningDiabetes Insipidus, Nephrogenic1
Not AvailableRecruitingDiagnosticHeart Failure, Unspecified1

Pharmacoeconomics

Manufacturers
  • Salix pharmaceuticals inc
  • Abc holding corp
  • Lederle laboratories div american cyanamid co
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Lundbeck inc
  • App pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
TabletOral250 mg/1
TabletOral500 mg/1
InjectionIntravenous500 mg/1
Injection, powder, lyophilized, for solutionIntravenous500 mg/18mL
SuspensionOral250 mg/5mL
InjectionIntravenous.5 mg/18mL
TabletOral
Prices
Unit descriptionCostUnit
Diuril sodium 500 mg vial519.62USD vial
Chlorothiazide sod 500 mg vial357.24USD vial
Microzide 12.5 mg capsule0.95USD capsule
Aldoclor 250-250 mg tablet0.67USD tablet
Chlorothiazide 500 mg tablet0.36USD tablet
Chlorothiazide 250 mg tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)342.5-343Novello, F.C.; US. Patent 2,809,194; October 8,1957; assigned to Merck & Co.,Inc. Hinkley, D.F.; US. Patent 2,937,169; May 17,1960; assigned to Merck & Co., Inc.
water solubility266 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.24HANSCH,C ET AL. (1995)
logS-3.05ADME Research, USCD
Caco2 permeability-6.72ADME Research, USCD
pKa6.85MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.398 mg/mLALOGPS
logP0.41ALOGPS
logP-0.44ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)9.1ChemAxon
pKa (Strongest Basic)1.15ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area118.69 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity62.51 m3·mol-1ChemAxon
Polarizability24.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9119
Blood Brain Barrier-0.9506
Caco-2 permeable-0.7368
P-glycoprotein substrateNon-substrate0.706
P-glycoprotein inhibitor INon-inhibitor0.8482
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.755
CYP450 2D6 substrateNon-substrate0.8379
CYP450 3A4 substrateNon-substrate0.6308
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9382
CYP450 3A4 inhibitorNon-inhibitor0.8901
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8658
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7792
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.5023 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9654
hERG inhibition (predictor II)Non-inhibitor0.9352
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.1 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-e74dd6446e0284a7f0aa
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-baf93e639a13c39dc1d6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01ox-0090000000-473477518be3f6c8ddcd
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0290000000-0e599c26917ade291ca0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0890000000-ad270ef1247ce9a114ad
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0920000000-3c4bb920bb8316022718
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-2900000000-eca13dbca70054de3470
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-02vr-9700000000-9261e1bf4e212aee7d84
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0i09-9100000000-491baf01fc6ef9ca39e1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0090000000-388cb4ff11dc0a41ad99
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002b-0090000000-5645eee512f78cd689a7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0390000000-a39ffe78224ed4cacc13
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pbl-0920000000-eb979e3c4ecd1f12fb71
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-059f-2900000000-4c2eb27958fba0102431
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05tk-5900000000-b42b446bc2b9f6216af1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kk-9400000000-b4b975e3c1fabe09f4a7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-9100000000-f8f80586b12a43c2a667
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-9000000000-9d41a0f061f998097c17

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiadiazines
Sub Class
Benzothiadiazines
Direct Parent
1,2,4-benzothiadiazine-1,1-dioxides
Alternative Parents
Organosulfonamides / Benzenoids / Aryl chlorides / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Formamidines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Organic oxides
show 1 more
Substituents
1,2,4-benzothiadiazine-1,1-dioxide / Aryl chloride / Aryl halide / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl / Aminosulfonyl compound / Propargyl-type 1,3-dipolar organic compound
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzothiadiazine (CHEBI:3640)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name
SLC12A3
Uniprot ID
P55017
Uniprot Name
Solute carrier family 12 member 3
Molecular Weight
113138.04 Da
References
  1. Thakker RV: Molecular pathology of renal chloride channels in Dent's disease and Bartter's syndrome. Exp Nephrol. 2000 Nov-Dec;8(6):351-60. [PubMed:11014932]
  2. Schmidt H, Kabesch M, Schwarz HP, Kiess W: Clinical, biochemical and molecular genetic data in five children with Gitelman's syndrome. Horm Metab Res. 2001 Jun;33(6):354-7. [PubMed:11456284]
  3. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP: Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):680-4. Epub 2003 Jan 6. [PubMed:12515852]
  4. Maki N, Komatsuda A, Wakui H, Ohtani H, Kigawa A, Aiba N, Hamai K, Motegi M, Yamaguchi A, Imai H, Sawada K: Four novel mutations in the thiazide-sensitive Na-Cl co-transporter gene in Japanese patients with Gitelman's syndrome. Nephrol Dial Transplant. 2004 Jul;19(7):1761-6. Epub 2004 Apr 6. [PubMed:15069170]
  5. Reinalter SC, Jeck N, Peters M, Seyberth HW: Pharmacotyping of hypokalaemic salt-losing tubular disorders. Acta Physiol Scand. 2004 Aug;181(4):513-21. [PubMed:15283765]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865]
  2. Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Weiner ID, Verlander JW: Renal and hepatic expression of the ammonium transporter proteins, Rh B Glycoprotein and Rh C Glycoprotein. Acta Physiol Scand. 2003 Dec;179(4):331-8. [PubMed:14656370]
  2. Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127]
  3. Verlander JW, Miller RT, Frank AE, Royaux IE, Kim YH, Weiner ID: Localization of the ammonium transporter proteins RhBG and RhCG in mouse kidney. Am J Physiol Renal Physiol. 2003 Feb;284(2):F323-37. Epub 2002 Oct 8. [PubMed:12388412]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina an...
Gene Name
CA4
Uniprot ID
P22748
Uniprot Name
Carbonic anhydrase 4
Molecular Weight
35032.075 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865]
  2. Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:43